Stable glucagon formulations for the treatment of hypoglycemia

US9687527B2 · kind B2 · utility

Assignees

• The Regents of the University of Colorado, a Body Corporate · US
• XERIS PHARMACEUTICALS, INC. · US

Inventors

• Steven Prestrelski · Chicago, US
• Wei-Jie Fang · Aurora, US
• John Carpenter · Littleton, US
• John Kinzell · San Rafael, US

Key dates

• Filing date: Feb 21, 2014
• Grant date: Jun 27, 2017
• Expiry date: Feb 21, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P7/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable glucagon that is dissolved in a pharmaceutically acceptable carrier.